Ucb Inc Drug Patent Portfolio
Ucb Inc owns 11 orange book drugs protected by 63 US patents with Keppra Xr having the least patent protection, holding only 1 patent. And Fintepla with maximum patent protection, holding 30 patents. Given below is the list of Ucb Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10452815 | Control system for control of distribution of medication | 29 Dec, 2038 | Active |
| US10452815 | Control system for control of distribution of medication | 29 Jun, 2038 | Active |
| US10603290 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Feb, 2038 | Active |
| US11040018 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Feb, 2038 | Active |
| US11406606 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Feb, 2038 | Active |
| US11759440 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Feb, 2038 | Active |
| US11786487 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Feb, 2038 | Active |
| US10603290 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Aug, 2037 | Active |
| US11040018 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Aug, 2037 | Active |
| US11406606 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Aug, 2037 | Active |
| US11759440 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Aug, 2037 | Active |
| US11786487 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | 02 Aug, 2037 | Active |
| US10947183 | Fenfluramine compositions and methods of preparing the same | 20 Jun, 2037 | Active |
| US10947183 | Fenfluramine compositions and methods of preparing the same | 20 Dec, 2036 | Active |
| US10950331 | Control system for control of distribution of medication | 28 Mar, 2036 | Active |
| US10950331 | Control system for control of distribution of medication | 28 Sep, 2035 | Active |
| US10106579 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US10208089 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US10435438 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US10562934 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US10835574 | Modulators of complement activity | 12 Jun, 2035 | Active |
| US11014965 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US11535650 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US11752190 | Modulators of complement activity | 12 Jun, 2035 | Active |
| US11965040 | Modulation of complement activity | 12 Jun, 2035 | Active |
| US10478441 | Method for the treatment of Dravet syndrome | 03 Nov, 2033 | Active |
| US10478442 | Method for the treatment of Dravet Syndrome | 03 Nov, 2033 | Active |
| US12097206 | Method for the treatment of Dravet Syndrome | 03 Nov, 2033 | Active |
| US9549909 | Method for the treatment of dravet syndrome | 03 Nov, 2033 | Active |
| US9603814 | Method for the treatment of Dravet syndrome | 03 Nov, 2033 | Active |
| US9603815 | Method for the treatment of Dravet syndrome | 03 Nov, 2033 | Active |
| US9610260 | Method for the treatment of Dravet Syndrome | 03 Nov, 2033 | Active |
| US10478441 | Method for the treatment of Dravet syndrome | 03 May, 2033 | Active |
| US10478442 | Method for the treatment of Dravet Syndrome | 03 May, 2033 | Active |
| US12097206 | Method for the treatment of Dravet Syndrome | 03 May, 2033 | Active |
| US9549909 | Method for the treatment of dravet syndrome | 03 May, 2033 | Active |
| US9603814 | Method for the treatment of Dravet syndrome | 03 May, 2033 | Active |
| US9603815 | Method for the treatment of Dravet syndrome | 03 May, 2033 | Active |
| US9610260 | Method for the treatment of Dravet Syndrome | 03 May, 2033 | Active |
| US9925150 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | 01 Mar, 2032 | Active |
| US8802142 | Pharmaceutical compositions comprising levetiracetam and process for their preparation | 07 Dec, 2031 | Active |
| US8802142 | Pharmaceutical compositions comprising levetiracetam and process for their preparation | 07 Jun, 2031 | Active |
| US10130589 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | 22 Dec, 2030 | Active |
| US10350174 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine | 22 Dec, 2030 | Active |
| US10729653 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | 09 Apr, 2030 | Active |
| US7858122 | Extended release formulation of levetiracetam | 17 Sep, 2028 | Active |
| US8217033 | Methods and compositions for the delivery of a therapeutic agent | 18 Jan, 2028 | Active |
| US8809322 | Methods and compositions for the delivery of a therapeutic agent | 18 Jan, 2028 | Active |
| US9289432 | Methods and compositions for the delivery of a therapeutic agent | 18 Jan, 2028 | Active |
| US9687495 | Methods and systems for the delivery of a therapeutic agent | 18 Jan, 2028 | Active |
| US8246979 | Transdermal delivery system for the administration of rotigotine | 01 Sep, 2027 | Active |
| US6911461 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | 21 Feb, 2026 | Active |
| US8246980 | Transdermal delivery system | 27 Nov, 2025 | Active |
| US8617591 | Transdermal delivery system for the administration of rotigotine | 22 Jul, 2023 | Expired |
| USRE38551 | Anticonvulsant enantiomeric amino acid derivatives | 17 Mar, 2022 | Expired |
| US6884434 | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof | 30 Mar, 2021 | Expired |
| US6784197 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | 21 Feb, 2021 | Expired |
| US8492416 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | 21 Feb, 2021 | Expired |
| US6699498 | Transdermal therapeutic systems having improved stability and their production | 27 Nov, 2020 | Expired |
| US7413747 | Transdermal therapeutic system for treating Parkinsonism | 18 Mar, 2019 | Expired |
| US6024981 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US6221392 | Rapidly dissolving robust dosage form | 09 Apr, 2018 | Expired |
| US5654301 | Amino acid derivative anticonvulsant | 05 Aug, 2014 | Expired |
Latest Legal Activities on Ucb Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ucb Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549909 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10208089 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10106579 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10562934 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 May, 2024 | US10835574 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10106579 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10835574 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10562934 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Apr, 2024 | US10208089 |
| Court Processing Terminated | 16 Apr, 2024 | US8246980 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8246980 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8246979 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jan, 2024 | US10729653 |
| Initial letter Re: PTE Application to regulating agency | 11 Jan, 2024 | US10106579 |
| Initial letter Re: PTE Application to regulating agency | 11 Jan, 2024 | US10208089 |
Ucb Inc's Drug Patent Litigations
Ucb Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 27, 2018, against patent number US10729653. The petitioner , challenged the validity of this patent, with Serge Cuypers et al as the respondent. Click below to track the latest information on how companies are challenging Ucb Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10729653 | November, 2018 |
Decision
(27 Jun, 2019)
| Serge Cuypers et al | |
Ucb Inc Drug Patents' Oppositions Filed in EPO
Ucb Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 09, 2015, by Cooke, Richard. This opposition was filed on patent number EP06776372A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15813093A | Jul, 2022 | Elkington and Fife LLP | Granted and Under Opposition |
| EP18152406A | Dec, 2021 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
| EP18152406A | Nov, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP16879990A | Sep, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP16879990A | Sep, 2021 | OLON S.p.A. | Granted and Under Opposition |
| EP10796399A | Mar, 2019 | Generics [U.K.] Limited | Opposition rejected |
| EP10796399A | Mar, 2019 | Luye Supply AG | Opposition rejected |
| EP14724037A | Dec, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP06776372A | Jun, 2015 | Cooke, Richard | Revoked |
Ucb Inc's Family Patents
Ucb Inc Drug List
Given below is the complete list of Ucb Inc's drugs and the patents protecting them.
1. Briviact
Briviact is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10729653 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
09 Apr, 2030
(5 years from now)
| Active |
| US6911461 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
21 Feb, 2026
(1 year, 2 months from now)
| Active |
| US6784197 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
21 Feb, 2021
(3 years ago)
| Expired |
| US8492416 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
21 Feb, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Briviact's drug page
2. Fintepla
Fintepla is protected by 30 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10452815
(Pediatric)
| Control system for control of distribution of medication |
29 Dec, 2038
(14 years from now)
| Active |
| US10452815 | Control system for control of distribution of medication |
29 Jun, 2038
(13 years from now)
| Active |
| US10603290
(Pediatric)
| Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Feb, 2038
(13 years from now)
| Active |
| US11040018
(Pediatric)
| Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Feb, 2038
(13 years from now)
| Active |
| US11406606
(Pediatric)
| Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Feb, 2038
(13 years from now)
| Active |
| US11759440
(Pediatric)
| Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Feb, 2038
(13 years from now)
| Active |
| US11786487
(Pediatric)
| Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Feb, 2038
(13 years from now)
| Active |
| US10603290 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Aug, 2037
(12 years from now)
| Active |
| US11040018 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Aug, 2037
(12 years from now)
| Active |
| US11406606 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Aug, 2037
(12 years from now)
| Active |
| US11759440 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Aug, 2037
(12 years from now)
| Active |
| US11786487 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
02 Aug, 2037
(12 years from now)
| Active |
| US10947183
(Pediatric)
| Fenfluramine compositions and methods of preparing the same |
20 Jun, 2037
(12 years from now)
| Active |
| US10947183 | Fenfluramine compositions and methods of preparing the same |
20 Dec, 2036
(12 years from now)
| Active |
| US10950331
(Pediatric)
| Control system for control of distribution of medication |
28 Mar, 2036
(11 years from now)
| Active |
| US10950331 | Control system for control of distribution of medication |
28 Sep, 2035
(10 years from now)
| Active |
| US10478441
(Pediatric)
| Method for the treatment of Dravet syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US10478442
(Pediatric)
| Method for the treatment of Dravet Syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US12097206
(Pediatric)
| Method for the treatment of Dravet Syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US9549909
(Pediatric)
| Method for the treatment of dravet syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US9603814
(Pediatric)
| Method for the treatment of Dravet syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US9603815
(Pediatric)
| Method for the treatment of Dravet syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US9610260
(Pediatric)
| Method for the treatment of Dravet Syndrome |
03 Nov, 2033
(8 years from now)
| Active |
| US10478441 | Method for the treatment of Dravet syndrome |
03 May, 2033
(8 years from now)
| Active |
| US10478442 | Method for the treatment of Dravet Syndrome |
03 May, 2033
(8 years from now)
| Active |
| US12097206 | Method for the treatment of Dravet Syndrome |
03 May, 2033
(8 years from now)
| Active |
| US9549909 | Method for the treatment of dravet syndrome |
03 May, 2033
(8 years from now)
| Active |
| US9603814 | Method for the treatment of Dravet syndrome |
03 May, 2033
(8 years from now)
| Active |
| US9603815 | Method for the treatment of Dravet syndrome |
03 May, 2033
(8 years from now)
| Active |
| US9610260 | Method for the treatment of Dravet Syndrome |
03 May, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fintepla's drug page
3. Fluxid
Fluxid is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fluxid's drug page
4. Kemstro
Kemstro is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kemstro's drug page
5. Keppra
Keppra is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8802142
(Pediatric)
| Pharmaceutical compositions comprising levetiracetam and process for their preparation |
07 Dec, 2031
(7 years from now)
| Active |
| US8802142 | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
07 Jun, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Keppra's drug page
Explore Our Curated Drug Screens
6. Keppra Xr
Keppra Xr is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7858122 | Extended release formulation of levetiracetam |
17 Sep, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Keppra Xr's drug page
7. Nayzilam
Nayzilam is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8217033 | Methods and compositions for the delivery of a therapeutic agent |
18 Jan, 2028
(3 years from now)
| Active |
| US8809322 | Methods and compositions for the delivery of a therapeutic agent |
18 Jan, 2028
(3 years from now)
| Active |
| US9289432 | Methods and compositions for the delivery of a therapeutic agent |
18 Jan, 2028
(3 years from now)
| Active |
| US9687495 | Methods and systems for the delivery of a therapeutic agent |
18 Jan, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nayzilam's drug page
8. Neupro
Neupro is protected by 9 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9925150 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
01 Mar, 2032
(7 years from now)
| Active |
| US10130589 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
22 Dec, 2030
(6 years from now)
| Active |
| US10350174 | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
22 Dec, 2030
(6 years from now)
| Active |
| US8246979 | Transdermal delivery system for the administration of rotigotine |
01 Sep, 2027
(2 years from now)
| Active |
| US8246980 | Transdermal delivery system |
27 Nov, 2025
(1 year, 5 days from now)
| Active |
| US8617591 | Transdermal delivery system for the administration of rotigotine |
22 Jul, 2023
(1 year, 4 months ago)
| Expired |
| US6884434 | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
30 Mar, 2021
(3 years ago)
| Expired |
| US6699498 | Transdermal therapeutic systems having improved stability and their production |
27 Nov, 2020
(3 years ago)
| Expired |
| US7413747 | Transdermal therapeutic system for treating Parkinsonism |
18 Mar, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neupro's drug page
9. Niravam
Niravam is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6024981 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
| US6221392 | Rapidly dissolving robust dosage form |
09 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Niravam's drug page
10. Vimpat
Vimpat is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE38551 | Anticonvulsant enantiomeric amino acid derivatives |
17 Mar, 2022
(2 years ago)
| Expired |
| US5654301 | Amino acid derivative anticonvulsant |
05 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vimpat's drug page
11. Zilbrysq
Zilbrysq is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10106579 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US10208089 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US10435438 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US10562934 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US10835574 | Modulators of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US11014965 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US11535650 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US11752190 | Modulators of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
| US11965040 | Modulation of complement activity |
12 Jun, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zilbrysq's drug page